» Articles » PMID: 35163063

The Optimized Delivery of Triterpenes by Liposomal Nanoformulations: Overcoming the Challenges

Overview
Journal Int J Mol Sci
Publisher MDPI
Date 2022 Feb 15
PMID 35163063
Authors
Affiliations
Soon will be listed here.
Abstract

The last decade has witnessed a sustained increase in the research development of modern-day chemo-therapeutics, especially for those used for high mortality rate pathologies. However, the therapeutic landscape is continuously changing as a result of the currently existing toxic side effects induced by a substantial range of drug classes. One growing research direction driven to mitigate such inconveniences has converged towards the study of natural molecules for their promising therapeutic potential. Triterpenes are one such class of compounds, intensively investigated for their therapeutic versatility. Although the pharmacological effects reported for several representatives of this class has come as a well-deserved encouragement, the pharmacokinetic profile of these molecules has turned out to be an unwelcomed disappointment. Nevertheless, the light at the end of the tunnel arrived with the development of nanotechnology, more specifically, the use of liposomes as drug delivery systems. Liposomes are easily synthesizable phospholipid-based vesicles, with highly tunable surfaces, that have the ability to transport both hydrophilic and lipophilic structures ensuring superior drug bioavailability at the action site as well as an increased selectivity. This study aims to report the results related to the development of different types of liposomes, used as targeted vectors for the delivery of various triterpenes of high pharmacological interest.

Citing Articles

The Role of Pentacyclic Triterpenoids in Non-Small Cell Lung Cancer: The Mechanisms of Action and Therapeutic Potential.

Lee Y, Kwon R, Lee H, Chung J, Kim Y, Jeong H Pharmaceutics. 2025; 17(1).

PMID: 39861671 PMC: 11768946. DOI: 10.3390/pharmaceutics17010022.


Tuning of the Anti-Breast Cancer Activity of Betulinic Acid via Its Conversion to Ionic Liquids.

Ossowicz-Rupniewska P, Klebeko J, Georgieva I, Apostolova S, Struk L, Todinova S Pharmaceutics. 2024; 16(4).

PMID: 38675157 PMC: 11053683. DOI: 10.3390/pharmaceutics16040496.


Triterpenes Drug Delivery Systems, a Modern Approach for Arthritis Targeted Therapy.

Faustino C, Duarte N, Pinheiro L Pharmaceuticals (Basel). 2024; 17(1).

PMID: 38256888 PMC: 10819636. DOI: 10.3390/ph17010054.


Ethanolic Extract Propolis-Loaded Niosomes Diminish Phospholipase B1, Biofilm Formation, and Intracellular Replication of in Macrophages.

Kietrungruang K, Sookkree S, Sangboonruang S, Semakul N, Poomanee W, Kitidee K Molecules. 2023; 28(17).

PMID: 37687052 PMC: 10488685. DOI: 10.3390/molecules28176224.


Extracellular Vesicles Released by Genetically Modified Macrophages Activate Autophagy and Produce Potent Neuroprotection in Mouse Model of Lysosomal Storage Disorder, Batten Disease.

El-Hage N, Haney M, Zhao Y, Rodriguez M, Wu Z, Liu M Cells. 2023; 12(11).

PMID: 37296618 PMC: 10252192. DOI: 10.3390/cells12111497.


References
1.
Fuente M, Ravina M, Paolicelli P, Sanchez A, Seijo B, Alonso M . Chitosan-based nanostructures: a delivery platform for ocular therapeutics. Adv Drug Deliv Rev. 2009; 62(1):100-17. DOI: 10.1016/j.addr.2009.11.026. View

2.
Beduneau A, Saulnier P, Benoit J . Active targeting of brain tumors using nanocarriers. Biomaterials. 2007; 28(33):4947-67. DOI: 10.1016/j.biomaterials.2007.06.011. View

3.
Candido T, de Oliveira C, Bueno Ariede M, Velasco M, Rosado C, Baby A . Safety and Antioxidant Efficacy Profiles of Rutin-Loaded Ethosomes for Topical Application. AAPS PharmSciTech. 2018; 19(4):1773-1780. DOI: 10.1208/s12249-018-0994-3. View

4.
Kim Y, Chiang B, Wu X, Prausnitz M . Ocular delivery of macromolecules. J Control Release. 2014; 190:172-81. PMC: 4142116. DOI: 10.1016/j.jconrel.2014.06.043. View

5.
Rai S, Pandey V, Rai G . Transfersomes as versatile and flexible nano-vesicular carriers in skin cancer therapy: the state of the art. Nano Rev Exp. 2018; 8(1):1325708. PMC: 6167026. DOI: 10.1080/20022727.2017.1325708. View